HSV

Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights

Retrieved on: 
Thursday, March 28, 2024
Research, HSV, Assembly, Biotechnology, Partnership, Viral, Doctor of Philosophy, Safety, BeiGene, Simplex, Therapy, CMO

Revenues from collaborative research were $7.2 million for the year ended December 31, 2023.

Key Points: 
  • Revenues from collaborative research were $7.2 million for the year ended December 31, 2023.
  • Research and development expenses were $48.9 million for the year ended December 31, 2023, compared to $70.0 million in 2022.
  • General and administrative expenses were $22.9 million for the year ended December 31, 2023, compared to $24.1 million in 2022.
  • The investigational products and investigational product candidates referenced here have not been approved anywhere globally, and their safety and efficacy have not been established.

Viral Vector and Plasmid DNA Technologies and Global Market Analysis - A USD 7.1 Billion Market by 2028, Expansion of Biotechnological Applications Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 2, 2024
Cardiology, Biotechnology, Health, Pharmaceutical, Oncology, Health Technology, Other Science, Research, Infectious Diseases, Genetics, Science, AAV, Transfection, QC, HSV, Acute lymphoblastic leukemia, Growth, Prevalence, Cell, Incidence, ALL, Tissue, DNA, Mortality, Virus, Cancer, Human, Infection, World Health Organization, Neoplasm, Immunization, Safety, WHO, Therapy, Inosine pranobex, USD, DSM-IV codes, Tisagenlecleucel, Vaccine

The rising incidence and prevalence rate of cancer is considered a key factor in the growth of the global viral vector and plasmid DNA technologies market.

Key Points: 
  • The rising incidence and prevalence rate of cancer is considered a key factor in the growth of the global viral vector and plasmid DNA technologies market.
  • However, regulatory challenges, vector characterization, and QC testing, and manufacturing challenges have restrained growth in the global viral vector and plasmid DNA technologies market.
  • The global viral vector and plasmid DNA technologies market is segmented based on the product, application, and end-user.
  • Based on the product, the global viral vector and plasmid DNA technologies market further is analyzed into plasmid DNA and viral vectors.

The Port of Huntsville Marks Another Year of Growth in Intermodal Transportation

Retrieved on: 
Wednesday, March 27, 2024
Norfolk Southern Railway, HSV, Huntsville International Airport, Partnership, Boeing, City, Investment, Intermodal transport, Atmosphere, DSV, Middle Tennessee, Kerry Logistics, Port, United States Customs Service

HUNTSVILLE, Ala., March 27, 2024 /PRNewswire/ -- The International Intermodal Center at the Port of Huntsville announces another year of exceptional growth in 2023.

Key Points: 
  • HUNTSVILLE, Ala., March 27, 2024 /PRNewswire/ -- The International Intermodal Center at the Port of Huntsville announces another year of exceptional growth in 2023.
  • The Port of Huntsville saw rail lifts grow 24% in 2023 thanks to its unique amenities as North Alabama's inland port.
  • "The International Intermodal Center at the Port of Huntsville has proudly served North Alabama and South Central Tennessee with comprehensive, high-quality intermodal services since 1986," said Butch Roberts, CEO of the Port of Huntsville.
  • "Our partnership with the Port of Huntsville allows us to bring Alabama and Tennessee businesses access to major U.S. seaports.

Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Monday, February 26, 2024
Research, Investment, Form 10-K, Sale, Form, HSV, Society, KRYS, Immunotherapy, Trial of the century, Genotype, Eye, PI, Krystal, Transgene, European Medicines Agency, Security (finance), Pharmacology, NCT, DEB, Jeune, ID, ODD, AATD, Safety, Survival, Medicaid, IND, Bronchoscopy, IL-12, Gene, MAA, FDA, Patent, Priority review, Cell, Lung, Patient, Medicine, Pharmaceutical industry

(the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results and key business updates for the fourth quarter and year ending December 31, 2023.

Key Points: 
  • (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results and key business updates for the fourth quarter and year ending December 31, 2023.
  • Financial results for the quarter ended December 31, 2023:
    Cash, cash equivalents, and investments totaled $594.1 million on December 31, 2023.
  • The Company recorded net product revenue of $42.1 million from sales of VYJUVEK during the quarter ended December 31, 2023.
  • For additional information on the Company’s financial results for the year ended December 31, 2023, please refer to the Form 10-K filed with the Securities and Exchange Commission.

BioVaxys Announces Allowance of DPX-Related Patent for Japan and Filing of Additional International Patent Applications

Retrieved on: 
Tuesday, March 5, 2024
RSV, Cancer, Messenger, Infection, FRA, Patent, APC, PCT, Patent Cooperation Treaty, HSV, Antibody, IMV, Peptide, Antigen, Protein, Intellectual property, Zika virus, Immune system, Vaccine

This Patent was part of the extensive Intellectual Property portfolio recently acquired by BioVaxys from the former IMV, Inc.

Key Points: 
  • This Patent was part of the extensive Intellectual Property portfolio recently acquired by BioVaxys from the former IMV, Inc.
  • This Patent has already been issued in the US, and is currently pending in the EU.
  • BioVaxys also is pleased to announce it filed an international patent application through the Patent Cooperation Treaty ("PCT") from two pending patent applications in the US related to methods of formulating DPX™ compositions that comprise both a lipid-based adjuvant (i.e.
  • The PCT is a patent treaty with more than 150 member countries, makes it possible to seek patent protection for an invention simultaneously in a large number of countries by filing a single "international" patent application instead of filing several separate national or regional patent applications.

Assembly Biosciences Provides Anticipated Development Milestones for 2024

Retrieved on: 
Thursday, January 4, 2024
Assembly, Partnership, Outline, Biotechnology, HDV, HBV, Trial of the century, Hepatitis B, Viral, HSV, Patient, Gilead Sciences, Vaccine

Four development candidates anticipated to be in the clinic by the end of 2024, reflecting expansion of R&D portfolio across herpesviruses and hepatitis B and D viruses

Key Points: 
  • Four development candidates anticipated to be in the clinic by the end of 2024, reflecting expansion of R&D portfolio across herpesviruses and hepatitis B and D viruses
    Recently announced long-term partnership with Gilead Sciences, Inc. (Gilead) to address serious viral diseases expands and builds on the progress of Assembly Bio’s antiviral portfolio
    SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today provided an outline of the anticipated milestones and progress for its clinical pipeline during 2024.
  • “We are thrilled with the rapid progress of multiple programs from our expanded antiviral pipeline, and plan to initiate clinical studies for four development candidates in 2024,” said Jason Okazaki, chief executive officer and president of Assembly Bio.
  • By the end of 2024:
    Two additional candidates are anticipated to enter the clinic:
    ABI-1179, the long-acting HSV helicase-primase inhibitor contributed by Gilead under the collaboration between Assembly Bio and Gilead; and
    ABI-6250, a small molecule orally-bioavailable hepatitis delta virus entry inhibitor.
  • Initial clinical data are expected to be available from both the ABI-5366 first-in-human clinical study and the ABI-4334 Phase 1b study.

CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO

Retrieved on: 
Tuesday, November 21, 2023
Partnership, HIV/AIDS, RSV, University, Biotechnology, CFO, Principal, Medical director, Hepatitis B, CMV, HPV, Therapy, Virus, Viral, Knowledge, Chairperson, COVID-19, OTCQB, HSV, CCR5, Internal medicine, Patient, Pharmaceutical industry

VANCOUVER, Washington, Nov. 21, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the appointment of Dr. Jacob Lalezari as interim CEO, effective November 17, 2023.

Key Points: 
  • VANCOUVER, Washington, Nov. 21, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the appointment of Dr. Jacob Lalezari as interim CEO, effective November 17, 2023.
  • Dr. Lalezari brings over 34 years of industry experience and has been a longtime adviser to the Company.
  • He previously served as interim Chief Medical Officer of CytoDyn during 2020, and has been a member of the Company’s scientific advisory board for the past several years.
  • Dr. Lalezari has been the CEO and Medical Director of Quest Clinical Research since 1996, and also served as the Chief Medical Officer of Virion Therapeutics in 2018.

Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, November 9, 2023
Science, Research, Solar eclipse of August 21, 2017, Therapy, Injection, Doctor of Philosophy, HGG, CD8, SITC, Disease, Risk, Annual general meeting, Cancer, Insurance, Break, Society for Immunotherapy of Cancer, MOS, CADL, Prostate cancer, Immune system, Antibody, Breast cancer, Pancreatic cancer, Biomarker, Safety, Patient, Administration, Cohort, Survivor, MD, Rated R, CA19-9, Development, Immunotherapy, Clinical trial, SOC, Arm, Society, Content discovery platform, Survival, Progression-free survival, HSV, HSV-1, Valaciclovir, Herpes simplex, Quarter, B cell, Vaccine, Pharmaceutical industry, NSCLC, Nature, Candel, PDAC, Fellow of the Academy of Medical Sciences

“We are encouraged by the recent clinical and biomarker data for CAN-2409 in NSCLC and pancreatic cancer, and CAN-3110 in recurrent HGG.

Key Points: 
  • “We are encouraged by the recent clinical and biomarker data for CAN-2409 in NSCLC and pancreatic cancer, and CAN-3110 in recurrent HGG.
  • Research and Development Expenses: Research and development expenses were $5.8 million for the third quarter of 2023 compared to $5.4 million for the third quarter of 2022.
  • Research and development expenses included non-cash stock compensation expense of $0.3 million for both the third quarter of 2023 and the third quarter of 2022.
  • General and administrative expenses included non-cash stock compensation expense of $0.4 million for both the third quarter of 2023 and the third quarter of 2022.

Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates

Retrieved on: 
Wednesday, November 8, 2023
Research, IND, American Association for the Study of Liver Diseases, International, Infection, HSV, Therapy, Hepatology, Viral, Biotechnology, Liver, Viral hepatitis, Hepatitis D, Doctor of Philosophy, Gilead Sciences, Assembly, Partnership, Virology, Hepatitis B, Patient, HDV, HBV, AASLD, Pharmaceutical industry, Vaccine, Birth control, MD

Established partnership with Gilead Sciences to advance differentiated treatments for herpesviruses, HBV, HDV and beyond

Key Points: 
  • Established partnership with Gilead Sciences to advance differentiated treatments for herpesviruses, HBV, HDV and beyond
    SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today reported financial results for the third quarter ended September 30, 2023, and recent corporate updates.
  • We believe that the financial and scientific resources provided by the collaboration position us well to reach critical short- and long-term milestones and deliver value for patients and our shareholders.
  • Partnership includes Gilead opt-in rights on Assembly Bio’s current and future pipeline candidates, including two contributed Gilead herpesvirus programs.
  • Cash, cash equivalents and marketable securities were $46.2 million as of September 30, 2023, compared to $59.8 million as of June 30, 2023.

Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC

Retrieved on: 
Saturday, November 4, 2023
Research, Arm, Society for Immunotherapy of Cancer, Intelligence, HSV, Therapy, Enlightenment, ICI, Herpes simplex virus, CADL, MD, Doctor of Philosophy, Nature, SITC, Immunotherapy, Neoplasm, Biology, Drug discovery, Machine learning, Annual general meeting, Tumor microenvironment, Bone marrow, Patient, Toxicity, Content discovery platform, Vaccine, Pharmaceutical industry, Candel, Fellow of the Academy of Medical Sciences

“We aim to leverage artificial intelligence and machine learning to expedite various aspects of drug discovery and development,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel.

Key Points: 
  • “We aim to leverage artificial intelligence and machine learning to expedite various aspects of drug discovery and development,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel.
  • “Tumor resistance to immunotherapy is driven by multiple mechanisms, which are heterogeneous in nature,” said Francesca Barone, MD, PhD, Chief Scientific Officer at Candel.
  • “The Alpha-201-macro1 preclinical data presented today support the utility of local delivery of an immunologically active, multimodal agent as a potential alternative to systemic therapy.
  • We are excited to leverage the enLIGHTEN™ Discovery Platform to optimize the immunostimulatory payload of this agent for activation of innate immune surveillance with the goal of maximizing its therapeutic potential.”
    Further details from the posters are available on the Candel website at: www.candeltx.com/media